Multiple-level validation identifies PARK2 in the development of lung cancer and chronic obstructive pulmonary disease

Seung Baek Lee, Jun She, Bo Deng, Jung Jin Kim, Mariza de Andrade, Jie Na, Zhifu Sun, Jason A. Wampfler, Julie M. Cunningham, Yanhong Wu, Andrew H. Limper, Marie Christine Aubry, Chris Wendt, Peter Biterman, Ping Yang, Zhenkun Lou

Research output: Contribution to journalArticlepeer-review

31 Scopus citations

Abstract

An important precursor to lung cancer development is chronic obstructive pulmonary disease (COPD), independent of exposure to tobacco smoke. Both diseases are associated with increased host susceptibility, inflammation, and genomic instability. However, validation of the candidate genes and functional confirmation to test shared genetic contribution and cellular mechanisms to the development of lung cancer in patients with COPD remains underexplored. Here, we show that loss of PARK2 (encoding Parkin) increases the expression of proinflammation factors as well as nuclear NF-κB localization, suggesting a role of PARK2 loss in inflammation. Additional exploration showed that PARK2 deficiency promotes genomic instability and cell transformation. This role of PARK2 in inflammation and chromosome instability provides a potential link among Parkin, COPD and lung cancer. A further comprehensive validation of 114 informative single nucleotide polymorphism (SNP) variants of PARK2, in 2,484 cases and controls with well-defined lung cancer and COPD phenotypes, found rs577876, rs6455728 and rs9346917 (p < 0.01) to be significantly associated with lung cancer development in people with COPD. Our findings support the evidence that PARK2 might have a tumor suppressor role in the development of COPD and lung cancer.

Original languageEnglish (US)
Pages (from-to)44211-44223
Number of pages13
JournalOncotarget
Volume7
Issue number28
DOIs
StatePublished - 2016

Bibliographical note

Funding Information:
The study was supported by the National Heart, Lung, and Blood Institute (NHLBI) grant, R01-HL107612 (Yang and Wendt), and National Cancer Institute grants, R01-CA80127 (Yang), R01-CA84354 (Yang), R01-CA130996 (Lou), R01-CA108961 (Lou) and R01-CA148940 (Lou), and Mayo Clinic Foundation Funds (Yang and Lou), Mayo Clinic Cancer Center grant CA15083. We thank Dr. Thomas C. Smyrk (Mayo clinic) for IHC analysis. Jun She was supported by the National Natural Science Foundation for Young Scholars of China, No. 81200051 and Scientific Project for Fudan University, No. 20520133474. Bo Deng was supported by National Natural Science Foundation of China, No. 81101782 and Third Military Medical University MiaoPu project. Ola Larsson was supported by the Swedish Research Council and the Wallenbberg Academy Fellows Programme. Andrew Limper was supported by funds from the Annenberg Foundation. Biospeciens accessioning and processing, genotyping and RNA microarray analysis were supported partly by the Mayo Clinic Cancer Center grant CA15083.

Keywords

  • Chronic obstructive pulmonary disease
  • Inflammation
  • Lung cancer
  • PARK2

Fingerprint

Dive into the research topics of 'Multiple-level validation identifies PARK2 in the development of lung cancer and chronic obstructive pulmonary disease'. Together they form a unique fingerprint.

Cite this